Integra Lifesciences Holdings Corp  

(Public, NASDAQ:IART)   Watch this stock  
Find more results for Stuart Gorelick
45.73
-0.13 (-0.28%)
After Hours: 45.72 -0.01 (-0.01%)
Apr 23, 5:09PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 45.40 - 46.12
52 week 32.27 - 49.99
Open 45.77
Vol / Avg. 78,735.00/130,181.00
Mkt cap 1.49B
P/E     -
Div/yield     -
EPS -0.65
Shares 32.58M
Beta 0.99
Inst. own 77%
May 15, 2014
Integra LifeSciences Corporation at Bank of America Merrill Lynch Health Care Conference - 1:00PM EDT - Add to calendar
May 7, 2014
Integra LifeSciences Corporation at Deutsche Bank Healthcare Conference - 2:10PM EDT - Add to calendar
May 6, 2014
Integra LifeSciences Corporation Investor Day Meeting - 9:00AM EDT - Add to calendar
May 1, 2014
Q1 2014 Integra LifeSciences Corporation Earnings Release - 9:30AM EDT - Add to calendar
May 1, 2014
Q1 2014 Integra LifeSciences Corporation Earnings Conference Call - 8:30AM EDT - Add to calendar
Mar 11, 2014
Integra LifeSciences Corporation at Barclays Healthcare Conference
Feb 26, 2014
Integra LifeSciences Corporation at RBC Capital Markets Healthcare Conference
Feb 26, 2014
Integra LifeSciences Corporation at Citi Global Healthcare Conference
Feb 25, 2014
Q4 2013 Integra LifeSciences Corporation Earnings Release
Feb 25, 2014
Q4 2013 Integra LifeSciences Corporation Earnings Conference Call
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 5.52% -2.03%
Operating margin 8.17% -0.44%
EBITD margin - 10.78%
Return on average assets 4.11% -1.44%
Return on average equity 8.36% -2.86%
Employees 3,500 -
CDP Score - -

Address

311 Enterprise Drive
PLAINSBORO, NJ 08536
United States - Map
+1-609-2750500 (Phone)
+1-609-2755363 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Integra LifeSciences Holdings Corporation (Integra) is an integrated medical technology company. Integra offers solutions in orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery. It has developed numerous product lines for applications ranging from burn and deep tissue wounds to regeneration of dura mater in the brain and repair of nerve and tendon. It operates in five business segments: U.S. Neurosurgery, U.S. Extremities, U.S. Instruments, U.S. Spine and Other, and International. The International segment sells similar products to Europe, Middle East and Africa, and Central/South America, Asia-Pacific and Canada. On April 30, 2013, it released its Hollywood VI intervertebral body fusion device (IBD) system. In January 2014, Integra LifeSciences Holdings Corp completed the acquisition of DuraSeal product lines from Covidien. In January 2014, Covidien PLC completed the sale of its Confluent Surgical product line to the Company.

Officers and directors

Stuart M. Essig Ph.D. Chairman of the Board
Age: 52
Bio & Compensation  - Reuters
Peter J. Arduini President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
John B. Henneman III Corporate Vice President - Finance and Administration, Chief Financial Officer
Age: 51
Bio & Compensation  - Reuters
Padma Thiruvengadam Chief Human Resources Officer, Corporate Vice President
Age: 48
Bio & Compensation  - Reuters
Kenneth E. Burhop Ph.D. Chief Scientific Officer, Corporate Vice President
Bio & Compensation  - Reuters
Judith E. O'Grady Corporate Vice President - Global Regulatory Affairs, Corporate Compliance Officer
Age: 62
Bio & Compensation  - Reuters
John Mooradian Corporate Vice President - Global Operations and Supply Chain
Age: 57
Bio & Compensation  - Reuters
Jerry E. Corbin Corporate Vice President, Principal Accounting Officer, Corporate Controller
Age: 53
Bio & Compensation  - Reuters
Richard D. Gorelick Corporate Vice President, General Counsel, Administration, Secretary
Age: 52
Bio & Compensation  - Reuters
Mark A. Augusti Corporate Vice President, President, Orthopedics and Tissue Technologies
Bio & Compensation  - Reuters